Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor

Podobne zapisy

• Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
  od: Park, Sehhoon, i wsp.
  Wydane: (2015)
• Pretreatment neutrophil‐lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor‐mutant non‐small cell lung cancer patients treated with tyrosine kinase inhibitors
  od: Sim, Sung Hoon, i wsp.
  Wydane: (2015)
• Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
  od: Soomin Kim, i wsp.
  Wydane: (2025-02-01)
• The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
  od: Kim, Hyungjin, i wsp.
  Wydane: (2017)
• KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
  od: Park, Sehhoon, i wsp.
  Wydane: (2017)